Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans

Zeen TongNonclinical Development, Celgene Corporation, Summit, NJ, USA, Correspondence[email protected]

Christian AtsrikuNonclinical Development, Celgene Corporation, Summit, NJ, USA,

Usha YerramilliNonclinical Development, Celgene Corporation, Summit, NJ, USA,

Xiaomin WangNonclinical Development, Celgene Corporation, Summit, NJ, USA,

Yan LiClinical Pharmacology, Celgene Corporation, Summit, NJ, USA, and

Josephine ReyesClinical Pharmacology, Celgene Corporation, Summit, NJ, USA, and

Bin FanDMPK/Clinical Pharmacology, Agios Pharmaceutical, Cambridge, MA, USA

Hua YangDMPK/Clinical Pharmacology, Agios Pharmaceutical, Cambridge, MA, USA

Matthew HoffmannNonclinical Development, Celgene Corporation, Summit, NJ, USA,

Sekhar SurapaneniNonclinical Development, Celgene Corporation, Summit, NJ, USA,

Your download is now in progress and you may close this window